Literature DB >> 8686718

Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy.

A W Heldman1, T V Hartert, S C Ray, E G Daoud, T E Kowalski, V J Pompili, S D Sisson, W C Tidmore, K A vom Eigen, S N Goodman, P S Lietman, B G Petty, C Flexner.   

Abstract

PURPOSE: To compare the efficacy and safety of inpatient oral antibiotic treatment (oral) versus standard parenteral antibiotic treatment (intravenous) for right-sided staphylococcal endocarditis in injection drug users. PATIENTS AND METHODS: In a prospective, randomized, non-blinded trial, febrile injection drug users were assigned to begin oral or intravenous (IV) treatment on admission, before blood culture results were available. Oral therapy consisted of ciprofloxacin and rifampin. Parenteral therapy was oxacillin or vancomycin, plus gentamicin for the first 5 days. Antibiotic dosing was adjusted for renal dysfunction. Administration of other antibacterial drugs was not permitted during the treatment or follow-up periods. Bacteremic subjects having right-sided staphylococcal endocarditis received 28 days of inpatient therapy with the assigned antibiotics. Test-of-cure blood cultures were obtained during inpatient observation 6 and 7 days after the completion of antibiotic therapy, and again at outpatient follow-up 1 month later. Criteria for treatment failure and for drug toxicity were prospectively defined.
RESULTS: Of 573 injection drug users who were hospitalized because of a febrile illness and suspected right-sided staphylococcal endocarditis, 93 subjects (16.2%) had two or more sets of blood cultures positive for staphylococci; 85 of these bacteremic subjects (14.8%) satisfied diagnostic criteria for at least possible right-sided staphylococcal endocarditis (no other source of bacteremia was apparent) and entered the trial. Forty-four (oral, 19; IV, 25) of these 85 subjects completed inpatient treatment and evaluation including test-of-cure blood cultures. There were four treatment failures (oral, 1 [5.2%]; IV, 3 [12.0%]; not significant, Fisher's exact test). Drug toxicity was significantly more common in the parenterally treated group (oral, 3%; IV, 62%; P < 0.0001), consisting largely of oxacillin-associated increases in liver enzymes.
CONCLUSIONS: For selected patients with right-sided staphylococcal endocarditis, oral ciprofloxacin plus rifampin is effective and is associated with less drug toxicity than is intravenous therapy.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8686718     DOI: 10.1016/s0002-9343(96)00070-8

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  47 in total

1.  Long-term antibiotic therapy in patients with surgery-indicated not undergoing surgery infective endocarditis.

Authors:  Nuria Vallejo Camazon; Lourdes Mateu; Germán Cediel; Laura Escolà-Vergé; Nuria Fernández-Hidalgo; Mercedes Gurgui Ferrer; Maria Teresa Perez Rodriguez; Guillermo Cuervo; Raquel Nuñez Aragón; Cinta Llibre; Nieves Sopena; Maria Dolores Quesada; Elisabeth Berastegui; Albert Teis; Jorge Lopez Ayerbe; Gladys Juncà; Francisco Gual; Elena Ferrer Sistach; Ainhoa Vivero; Esteban Reynaga; Maria Hernández Pérez; Christian Muñoz Guijosa; Lluisa Pedro-Botet; Antoni Bayés-Genís
Journal:  Cardiol J       Date:  2021-05-25       Impact factor: 2.737

2.  Echocardiography for the Diagnosis of Staphylococcus aureus Infective Endocarditis.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-06       Impact factor: 3.725

Review 3.  Injection drug use and right sided endocarditis.

Authors:  Rob Moss; Brad Munt
Journal:  Heart       Date:  2003-05       Impact factor: 5.994

4.  [S2 Guideline for diagnosis and therapy of infectious endocarditis].

Authors:  C K Naber
Journal:  Z Kardiol       Date:  2004-12

5.  Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations.

Authors:  Brian T Tsuji; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2005-07       Impact factor: 5.191

6.  Daptomycin for infective endocarditis.

Authors:  Donald Levine
Journal:  Curr Infect Dis Rep       Date:  2006-06       Impact factor: 3.725

Review 7.  Epidemiology and antibiotic treatment of infective endocarditis: an update.

Authors:  Bruno Hoen
Journal:  Heart       Date:  2006-11       Impact factor: 5.994

Review 8.  Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials.

Authors:  W J Burman; K Gallicano; C Peloquin
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 9.  Rifamycins, Alone and in Combination.

Authors:  David M Rothstein
Journal:  Cold Spring Harb Perspect Med       Date:  2016-07-01       Impact factor: 6.915

10.  Infective Endocarditis in Intravenous Drug Abusers.

Authors:  José M. Miró; Asuncion Moreno; Carlos A. Mestres
Journal:  Curr Infect Dis Rep       Date:  2003-08       Impact factor: 3.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.